Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study.
Kohei FukuokaJun KuriharaTomoko ShofudaNaoki KagawaKai YamasakiRyo AndoJoji IshidaMasayuki KanamoriAtsufumi KawamuraYoung-Soo ParkChikako KiyotaniTakuya AkaiDai KeinoYosuke MiyairiAtsushi SasakiJunko HiratoTakeshi InoueAtsuko NakazawaKatsuyoshi KohRyo NishikawaIsao DateMotoo NaganeKoichi IchimuraYonehiro KanemuraPublished in: Acta neuropathologica communications (2023)
Although these findings require validation in a larger cohort, the present findings suggest that novel subtyping of Group 3/4 medulloblastoma may be a promising prognostic biomarker even among patients treated with lower-dose CSI than standard treatment.